Evolus, Inc. (EOLS) earnings
EOLS earnings moved a median of -2.45% by the close. Quarterly and annual EOLS reports and results, each read against the price at its own news timestamp. Back to the EOLS overview →
22 measured EOLS earnings events.
Where these EOLS earnings landedvs 22 measured EOLS earnings reactions
| Middle 50% of EOLS earnings reactions | -6.02% to +0.84% |
|---|---|
| Median reaction (to close) | -2.45% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 EOLS earnings events with a measured close landed between -6.02% and +0.84%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook | Press release | -2.86% | +6.01% | |
| Form 10-Q Evolus, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.86% | +6.01% | |
| Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook | Press release | +10.34% | +15.61% | |
| Form 10-Q Evolus, Inc. For: Mar 31 | SEC filing · Form 10-Q | +10.34% | +15.61% | |
| Form 10-K Evolus, Inc. For: Dec 31 | SEC filing · Form 10-K | +8.18% | +5.47% | |
| Evolus Reports Third Quarter 2025 Financial Results | Press release | -0.46% | -6.14% | |
| Form 10-Q Evolus, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.46% | -6.14% | |
| Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | -8.15% | -5.63% | |
| Form 10-Q Evolus, Inc. For: Jun 30 | SEC filing · Form 10-Q | -8.15% | -5.63% | |
| Evolus Reports First Quarter 2025 Results | Press release | -4.57% | -9.51% | |
| Form 10-Q Evolus, Inc. For: Mar 31 | SEC filing · Form 10-Q | -4.57% | -9.51% | |
| Form 10-K Evolus, Inc. For: Dec 31 | SEC filing · Form 10-K | -5.03% | -2.28% | |
| Evolus Reports Third Quarter 2024 Results | Press release | -1.70% | -6.36% | |
| Form 10-Q Evolus, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.70% | -6.36% | |
| Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance | Press release | +0.00% | +0.29% | |
| Form 10-Q Evolus, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.29% | |
| Evolus Reports First Quarter 2024 Results and Provides Business Update | Press release | +0.46% | +0.84% | |
| Form 10-Q Evolus, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.46% | +0.84% | |
| Form 10-K Evolus, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.28% | -2.63% | |
| Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau® | Press release | -4.87% | -5.51% | |
| Form 10-Q Evolus, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.87% | -5.51% | |
| Evolus to Report Third Quarter 2023 Results | Press release | +0.00% | -1.27% |
Keep exploring
More EOLS: analyst actions → · SEC filings → · EOLS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Anika Therapeutics Inc. (ANIK) | 275 | +0.07% | 52% |
| Delcath Systems, Inc. (DCTH) | 275 | -0.27% | 42% |
| LivaNova PLC - Ordinary Shares (LIVN) | 275 | +0.04% | 51% |
| Puma Biotechnology Inc (PBYI) | 274 | +0.44% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.